Qatar Launches 10,000-Patient AI-Powered Cardiometabolic Registry — Insights for Australian Cardiovascular Practice

References

1. 1.Weill Cornell Medical College in Qatar. (2024). Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence. ClinicalTrials.gov. NCT07515807. https://clinicaltrials.gov/study/NCT07515807
2. 2.Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovascular Diabetology, 17(1), 83. https://doi.org/10.1186/s12933-018-0728-6
3. 3.Sulaiman, N., Mahmoud, I., Hussein, A., Elbadawi, S., Abusnana, S., Zimmet, P., & Shaw, J. (2022). Diabetes epidemic in the Arab world. Lancet, 400(10365), 1865-1871. https://doi.org/10.1016/S0140-6736(22)00956-5
4. 4.Krittanawong, C., Zhang, H., Wang, Z., Aydar, M., & Kitai, T. (2017). Artificial Intelligence in Precision Cardiovascular Medicine. Journal of the American College of Cardiology, 69(21), 2657-2664. https://doi.org/10.1016/j.jacc.2017.03.571
5. 5.Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A. M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., & Gudbjörnsdottir, S. (2018). Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 379(7), 633-644. https://doi.org/10.1056/NEJMoa1800256